Clinical

Dataset Information

0

Phase1 trial of Panitumumab combined with S-1 and irrinotecan in advanced/metastatic colorectal cancer


ABSTRACT: Interventions: Panitumumab:Bi-weekly administration 6 mg/kg TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1,8 every 4 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 125mg/m2, day1 Primary outcome(s): Maximum tolerated dose Recommended dose Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620191 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2619160 | ecrin-mdr-crc
| 2618747 | ecrin-mdr-crc
| 2621739 | ecrin-mdr-crc
| 2622216 | ecrin-mdr-crc
| 2617187 | ecrin-mdr-crc
| 2627635 | ecrin-mdr-crc
| 2622299 | ecrin-mdr-crc
| 2622829 | ecrin-mdr-crc
| 2627425 | ecrin-mdr-crc
| 2621336 | ecrin-mdr-crc